Protagonist Therapeutics Q2 net loss beats expectations

Protagonist Therapeutics

06/08/2025 21:27

Overview

Protagonist Q2 net loss $34.8 mln, beating analyst expectations, per LSEG data

License and collaboration revenue rose to $5.5 mln in Q2

Income from operations missed expectations due to higher operating expenses

Outlook

Protagonist expects rusfertide NDA filing in Q4 2025

Company anticipates cash runway through end of 2028

Result Drivers

INCREASED R&D EXPENSES - Rise in R&D costs driven by new product candidates PN-881 and PN-477

LICENSE REVENUE GROWTH - License and collaboration revenue increased due to Takeda collaboration milestone

HIGHER G&A COSTS - Increase in G&A expenses attributed to stock-based compensation and personnel costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 License and Collaboration Revenue
$5.55 mln
Q2 EPS
-$0.55
Q2 Net Income
Beat
-$34.77 mln
-$35.10 mln (9 Analysts)
Q2 Income from Operations
Miss
-$42.04 mln
-$40.10 mln (10 Analysts)
Q2 Basic EPS
-$0.55
Q2 Operating Expenses
$47.59 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Protagonist Therapeutics Inc is $70.00, about 23% above its August 5 closing price of $53.90

Press Release: ID:nACSTBJnZa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)